Plymouth, MA, Dec 2, 2024 – MitoSense, Inc., a pioneering research and development
company focused on treatments for neurodegenerative diseases, is proud to announce
the issuance of U.S. Patent No. 12,150,958, titled “Compositions and Methods for
Treatment of Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative
Diseases, and Associated Methods for Preparing Said Compositions.” This patent
marks a significant milestone in the company's mission to develop groundbreaking
therapies.
The newly secured patent protects MitoSense’s proprietary techniques for Mitochondria
Organelle Transplantation (MOT™), a method aimed at replenishing mitochondria in
human cells to treat ALS and potentially a range of other neurodegenerative diseases,
including Alzheimer’s, Parkinson’s, Huntington’s, and Multiple Sclerosis. This innovative
approach, developed through extensive research, offers a promising avenue for
addressing diseases that currently lack effective cures.
MitoSense’s MOT™ technology is founded on a robust base of scientific innovation and
dedicated research, initiated by the late Dr. Robert Elliott, MD, PhD. The company’s
leadership team, composed of experts from the business, government, research, and
medical sectors, is committed to advancing Dr. Elliott’s legacy and providing hope for
patients and families affected by neurodegenerative diseases.
Van Hipp, Chairman of MitoSense, Inc., commented on the milestone:
“The issuance of this patent is a tremendous achievement for MitoSense and
underscores our commitment to innovation in the fight against neurodegenerative
diseases. Our MOT™ technology has the potential to revolutionize how we treat
conditions like ALS, Alzheimer’s, and Parkinson’s. This is a significant step forward in
our mission to bring transformative treatments to patients who desperately need them.”
About MitoSense Inc.
MitoSense Inc. is at the forefront of mitochondrial research, committed to developing
pioneering solutions that harness the potential of mitochondria to transform treatments
for various medical conditions.
For further information about MitoSense and its research efforts, visit
www.mitosense.com or contact the company at info@mitosense.com.